Defibrotide Sodium is Used for treating hepatic veno-occlusive disease following hematopoietic stem cell transplantation in adults and pediatric patients. It was first introduced by Jazz Pharmaceuticals Inc in its drug Defitelio on Mar 30, 2016.

Defibrotide Sodium Patents

Given below is the list of patents protecting Defibrotide Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Defitelio	US11085043	Euglobulin-based method for determining the biological activity of defibrotide	Jun 22, 2032	Jazz Pharms Inc
Defitelio	US11236328	Euglobulin-based method for determining the biological activity of defibrotide	Jun 22, 2032	Jazz Pharms Inc
Defitelio	US11746348	Euglobulin-based method for determining the biological activity of defibrotide	Jun 22, 2032	Jazz Pharms Inc

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳